Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers.
Campo F, Venuti A, Pimpinelli F, Abril E, Blandino G, Conti L, De Virgilio A, De Marco F, Di Noia V, Di Domenico EG, Di Martino S, Ensoli F, Giannarelli D, Mandoj C, Mazzola F, Moretto S, Petruzzi G, Petrone F, Pichi B, Pontone M, Vidiri A, Vujovic B, Piaggio G, Sperandio E, Rosati V, Cognetti F, Morrone A, Ciliberto G, Pellini R. Campo F, et al. Among authors: cognetti f. Vaccines (Basel). 2021 Oct 3;9(10):1125. doi: 10.3390/vaccines9101125. Vaccines (Basel). 2021. PMID: 34696233 Free PMC article.
Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.
Di Noia V, Pimpinelli F, Renna D, Barberi V, Maccallini MT, Gariazzo L, Pontone M, Monti A, Campo F, Taraborelli E, Di Santo M, Petrone F, Mandoj C, Ferraresi V, Ferretti G, Carlini P, Di Bella O, Conti L, La Malfa AM, Pellini R, Bracco D, Giannarelli D, Morrone A, Cognetti F. Di Noia V, et al. Among authors: cognetti f. Clin Cancer Res. 2021 Dec 15;27(24):6815-6823. doi: 10.1158/1078-0432.CCR-21-2439. Epub 2021 Sep 28. Clin Cancer Res. 2021. PMID: 34583970
Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
Di Noia V, Pimpinelli F, Renna D, Campo F, Cosimati A, Torchia A, Marcozzi B, Massacci A, Pallocca M, Pellini R, Morrone A, Cognetti F. Di Noia V, et al. Among authors: cognetti f. Eur J Cancer. 2022 Nov;176:164-167. doi: 10.1016/j.ejca.2022.09.006. Epub 2022 Oct 9. Eur J Cancer. 2022. PMID: 36223679 Free PMC article. No abstract available.
The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey.
Di Noia V, Renna D, Barberi V, Di Civita M, Riva F, Costantini G, Aquila ED, Russillo M, Bracco D, La Malfa AM, Giannarelli D, Cognetti F. Di Noia V, et al. Among authors: cognetti f. Eur J Cancer. 2021 Aug;153:260-264. doi: 10.1016/j.ejca.2021.05.006. Epub 2021 May 26. Eur J Cancer. 2021. PMID: 34183225 Free PMC article.
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.
Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, Cognetti F. Fabi A, et al. Among authors: cognetti f. BMC Cancer. 2012 Oct 19;12:482. doi: 10.1186/1471-2407-12-482. BMC Cancer. 2012. PMID: 23083011 Free PMC article.
407 results